The idea of a vaccine for cancer is not new. But there are differences between human viruses and cancer that make creation of a cancer vaccine particularly challenging.
Three teams receive awards from the Dartmouth Innovations Accelerator for Cancer
NH Cancer Researchers Find Cellular Evidence Behind Lasting Immune Response in Some Cancer Survivors
Researchers have found that a certain subpopulation of cells that enters a patient’s skin and blood during immunotherapy is behind the excellent and long-lasting immune responses to cancer that some survivors develop.
Combining high-dose radiation therapy with immunotherapy to treat cancer, and resolving employment challenges among cancer survivors are among the newest research projects funded by The Prouty.
Cherenkov imaging cameras invented by Dartmouth spinoff company and pioneered at NCCC allow radiation oncologists to visualize external beam field, improving quality, precision and patient safety during radiation therapy.
A Dartmouth faculty member, a husband grateful for the care his wife received, and a Dartmouth College alumna and her husband have made gifts to accelerate immunotherapy research at Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center.
The 40th Annual Prouty launches fundraising campaign for 2021.
Researchers convert a standard linear accelerator used for radiation therapy, to deliver an ultra-high-dose rate beam to cancer patients “in a flash.”
Researchers find a signaling pathway that limits mammary basal cells’ ability to fuel the growth of multiple aggressive cell populations within a breast tumor, uncovering opportunities for novel therapeutic approaches to breast cancer.
Dartmouth-Hitchcock Norris Cotton Cancer Center leads a new multi-center Phase I in-human clinical trial of anti-VISTA, a therapeutic antibody designed to target a molecule that keeps the immune system quiet against cancer.